<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Over the past 20 years, the number of invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> has continued to persist, due primarily to the increased numbers of patients subjected to severe immunosuppression </plain></SENT>
<SENT sid="1" pm="."><plain>Despite the development of more active, less toxic antifungal agents and the standard use of antifungal prophylaxis, invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> (especially invasive mold <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>) continue to be a significant factor in hematopoietic cell and solid organ transplantation outcomes, resulting in high mortality rates </plain></SENT>
<SENT sid="2" pm="."><plain>Since the use of <z:chebi fb="2" ids="46081">fluconazole</z:chebi> as standard prophylaxis in the hematopoietic cell transplantation setting, <z:e sem="disease" ids="C1609535" disease_type="Disease or Syndrome" abbrv="">invasive candidiasis</z:e> has come under control, but no mold-active <z:chebi fb="0" ids="35718">antifungal agent</z:chebi> (except for posaconazole in the setting of <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>) has been shown to improve the survival rate over <z:chebi fb="2" ids="46081">fluconazole</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>With the advent of new azole and echinocandin agents, we have seen the emergence of more azole-resistant and echinocandin-resistant fungi </plain></SENT>
<SENT sid="4" pm="."><plain>The recent increase in <z:e sem="disease" ids="C0043541" disease_type="Disease or Syndrome" abbrv="">zygomycosis</z:e> seen in the hematopoietic cell transplantation setting may be due to the increased use of <z:chebi fb="0" ids="10023">voriconazole</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>This has implications for the empiric approach to pulmonary invasive mold <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> when <z:e sem="disease" ids="C0043541" disease_type="Disease or Syndrome" abbrv="">zygomycosis</z:e> cannot be ruled out </plain></SENT>
<SENT sid="6" pm="."><plain>It is imperative that an <z:chebi fb="1" ids="2682">amphotericin B</z:chebi> product, an antifungal that has never developed resistance in over 50 years, be initiated </plain></SENT>
<SENT sid="7" pm="."><plain>The clinical presentations of invasive mold <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> and <z:e sem="disease" ids="C1609535" disease_type="Disease or Syndrome" abbrv="">invasive candidiasis</z:e> can be nonspecific and the diagnostic tests insensitive, so a high index of suspicion and immediate initiation of empiric therapy is required </plain></SENT>
<SENT sid="8" pm="."><plain>Unfortunately, our currently available serologic tests do not predict <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> ahead of disease, and, therefore cannot be used to initiate "preemptive" therapy </plain></SENT>
<SENT sid="9" pm="."><plain>Also, the Aspergillus galactomannan test gives a false negative result in patients receiving antimold prophylaxis, ie, virtually <z:hpo ids='HP_0000001'>all</z:hpo> of our patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancy</z:e> and hematopoietic cell transplant recipients </plain></SENT>
<SENT sid="10" pm="."><plain>We may eventually be able to select patients at highest risk for invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> for prophylaxis by genetic testing </plain></SENT>
<SENT sid="11" pm="."><plain>However, with our current armamentarium of antifungal agents and widespread use of prophylaxis in high-risk groups (<z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancy</z:e>, hematopoietic cell transplantation), we continue to see high incidence and mortality rates, and our future hope lies in reversing the immunosuppression or augmenting the immune system of these severely immunocompromised hosts by developing and utilizing immunotherapy, immunoprophylaxis, and vaccines </plain></SENT>
</text></document>